Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01983709 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01983709 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 7 participants.
The verdict
NCT01983709, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The objective of this study is to determine if systemically infused allogeneic bone marrow derived mesenchymal stem cells (MSC) home to sites of prostate cancer in men with localized adenocarcinoma of the prostate that are planning to undergo a prostatectomy. Investigators plan to systemically infuse MSCs 4, 6 or 8 days prior to enrolled subjects' planned prostatectomies. Investigators will then quantify the relative amount of donor MSC DNA to recipient DNA present in patients' explanted prostate specimens. This will be accomplished via BEAMing digital PCR. This trial will provide the foundation for future studies aimed at engineering MSCs to deliver a toxin to sites of metastatic prostate cancer.
Interventions
- BIOLOGICAL Allogeneic Human Mesenchymal Stem Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-10 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01983709
The ClinicalTrials.gov registry entry for NCT01983709 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic Human Mesenchymal Stem Cells is the first listed.
NCT01983709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01983709 about?
NCT01983709 is a clinical study titled "Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer". The objective of this study is to determine if systemically infused allogeneic bone marrow derived mesenchymal stem cells (MSC) home to sites of prostate cancer in men with localized adenocarcinoma of the prostate that are planning to undergo a prostatectomy. Investigators plan to systemically infus...
What is the current status of trial NCT01983709?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2013-10. Estimated completion is 2017-06.
What interventions are being tested in trial NCT01983709?
The interventions under investigation include: Allogeneic Human Mesenchymal Stem Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01983709?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.